What is the Parkinson's Virtual Biotech?
Founded by Parkinson’s UK in 2017, the Parkinson’s Virtual Biotech is now an international programme in partnership with the Parkinson’s Foundation. We believe we’ll get to a cure faster by collaborating, not competing.
We identify projects with the greatest potential to transform life for people with Parkinson’s. We then work with partners to rapidly develop and test them.
We’re already investing over £25 million in projects from early stage research to world-first phase 2 clinical trials of groundbreaking new treatments.
But our ambitions go much further.
We’re aiming to invest a further £20 million by 2026 to deliver life-changing new treatments for people with Parkinson’s in years not decades.
Our strategic partnership with Parkinson's Foundation
Arthur Roach, Director of the Parkinson's Virtual Biotech and John Lehr, President and CEO of the Parkinson's Foundation, talk about the impact of the Parkinson's Virtual Biotech on the future of Parkinson's research. And how collaboration can get us closer to new treatments faster.
Collaboration on a global scale
The Virtual Biotech is made up of:
- over 60 funders, research organisations, universities, biotech companies, trial centres, and charities, from France to Finland, China to Canada
- a long term, multi-million dollar strategic partnership with the Parkinson’s Foundation
- over 400 dedicated people stepping up to take part in pioneering clinical trials
- thousands of generous supporters uniting to find a cure.
Everyone can play a part in the search for a cure for Parkinson's. From funding to volunteering, the more people who get involved, the faster we'll get there.